Article (Scientific journals)
The role of metabolites and metabolomics in clinically applicable biomarkers of disease.
Mamas, Mamas; Dunn, Warwick B.; Neyses, Ludwig et al.
2011In Archives of Toxicology, 85 (1), p. 5-17
Peer Reviewed verified by ORBi


Full Text
The role of metabolites and metabolomics in clinically applicable.pdf
Publisher postprint (608.5 kB)
Request a copy

All documents in ORBilu are protected by a user license.

Send to


Keywords :
Biological Markers/metabolism; Cardiovascular Diseases/diagnosis; Drug-Related Side Effects and Adverse Reactions/diagnosis; Humans; Mass Spectrometry; Metabolomics/methods; Neoplasms/diagnosis; Research Design
Abstract :
[en] Metabolomics allows the simultaneous and relative quantification of thousands of different metabolites within a given sample using sensitive and specific methodologies such as gas or liquid chromatography coupled to mass spectrometry, typically in discovery phases of studies. Biomarkers are biological characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathological processes or pharmacologic responses to a therapeutic intervention. Biomarkers are widely used in clinical practice for the diagnosis, assessment of severity and response to therapy in a number of clinical disease states. In human studies, metabolomics has been applied to define biomarkers related to prognosis or diagnosis of a disease or drug toxicity/efficacy and in doing so hopes to provide greater pathophysiological understanding of disease or therapeutic toxicity/efficacy. This review discusses the application of metabolomics in the discovery and subsequent application of biomarkers in the diagnosis and management of inborn errors of metabolism, cardiovascular disease and cancer. We critically appraise how novel biomarkers discovered through metabolomic analysis may be utilized in future clinical practice by addressing the following three fundamental questions: (1) Can the clinician measure them? (2) Do they add new information? (3) Do they help the clinician to manage patients? Although a number of novel biomarkers have been discovered through metabolomic studies of human diseases in the last decade, none have currently made the transition to routine use in clinical practice. Metabolites identified from these early studies will need to form the basis of larger, prospective, externally validated studies in clinical cohorts for their future use as biomarkers. At this stage, the absolute quantification of these biomarkers will need to be assessed epidemiologically, as will the ultimate deployment in the clinic via routine biochemistry, dip stick or similar rapid at- or near-patient care technologies.
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Mamas, Mamas
Dunn, Warwick B.
Neyses, Ludwig ;  University of Luxembourg > Research Office
Goodacre, Royston
Language :
Title :
The role of metabolites and metabolomics in clinically applicable biomarkers of disease.
Publication date :
Journal title :
Archives of Toxicology
Publisher :
Springer, Germany
Volume :
Issue :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBilu :
since 16 October 2014


Number of views
70 (1 by Unilu)
Number of downloads
0 (0 by Unilu)

Scopus citations®
Scopus citations®
without self-citations
WoS citations


Similar publications

Contact ORBilu